Diurnal receives marketing authorisation for Efmody to treat congenital adrenal hyperplasia from the MHRA (UK)
Diurnal Group plc announces that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorisation for Efmody (hydrocortisone modified-release hard capsules – development name… read more.
